[{"Physician_Profile_ID": "1045914", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "18750.00", "Date_of_Payment": "10/11/2013", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "31639983", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://www.clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "1045914", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "7312.50", "Date_of_Payment": "11/27/2013", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "31639985", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://www.clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "1045914", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "7284.00", "Date_of_Payment": "08/15/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214164568", "Name_of_Associated_Covered_Drug_or_Biological1": "ORENITRAM", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "TRIAL OF THE EARLY COMBINATION OF ORAL TREPROSTINIL WITH A PDE-5 INHIBITOR OR ERA IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION FREEDOM EV", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01560624", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "1045914", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "6682.00", "Date_of_Payment": "09/05/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214164574", "Name_of_Associated_Covered_Drug_or_Biological1": "ORENITRAM", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "TRIAL OF THE EARLY COMBINATION OF ORAL TREPROSTINIL WITH A PDE-5 INHIBITOR OR ERA IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION FREEDOM EV", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01560624", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "1045914", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "5375.00", "Date_of_Payment": "11/13/2013", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "31639984", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "STUDY OF INCIDENCE OF RESPIRATORY TRACT AES IN PATIENTS TREATED WITH TYVASO COMPARED TO OTHER FDA APPROVED PAH THERAPIES ASPIRE", "Research_Information_Link": "http://www.clinicaltrials.gov/ct2/show/NCT01266265", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "1045914", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "5324.00", "Date_of_Payment": "05/23/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214164556", "Name_of_Associated_Covered_Drug_or_Biological1": "ORENITRAM", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "TRIAL OF THE EARLY COMBINATION OF ORAL TREPROSTINIL WITH A PDE-5 INHIBITOR OR ERA IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION FREEDOM EV", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01560624", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "1045914", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "5212.00", "Date_of_Payment": "08/15/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214164566", "Name_of_Associated_Covered_Drug_or_Biological1": "ORENITRAM", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "TRIAL OF THE EARLY COMBINATION OF ORAL TREPROSTINIL WITH A PDE-5 INHIBITOR OR ERA IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION FREEDOM EV", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01560624", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "1045914", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "5046.00", "Date_of_Payment": "02/21/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214164548", "Name_of_Associated_Covered_Drug_or_Biological1": "ORENITRAM", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "TRIAL OF THE EARLY COMBINATION OF ORAL TREPROSTINIL WITH A PDE-5 INHIBITOR OR ERA IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION FREEDOM EV", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01560624", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "1045914", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "4706.00", "Date_of_Payment": "09/05/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214164572", "Name_of_Associated_Covered_Drug_or_Biological1": "ORENITRAM", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "TRIAL OF THE EARLY COMBINATION OF ORAL TREPROSTINIL WITH A PDE-5 INHIBITOR OR ERA IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION FREEDOM EV", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01560624", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "1045914", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "3441.00", "Date_of_Payment": "10/24/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214164576", "Name_of_Associated_Covered_Drug_or_Biological1": "ORENITRAM", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "TRIAL OF THE EARLY COMBINATION OF ORAL TREPROSTINIL WITH A PDE-5 INHIBITOR OR ERA IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION FREEDOM EV", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01560624", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "1045914", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "2625.00", "Date_of_Payment": "03/06/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214164552", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "AN OPEN LABEL EXTENSION TRIAL OF UT15C SR IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION FREEDOM EXT", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01027949", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "1045914", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "2625.00", "Date_of_Payment": "03/06/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214164550", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "AN OPEN LABEL EXTENSION TRIAL OF UT15C SR IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION FREEDOM EXT", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01027949", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "1045914", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "2625.00", "Date_of_Payment": "03/06/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214164554", "Name_of_Associated_Covered_Drug_or_Biological1": "TYVASO", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "AN OPEN LABEL EXTENSION TRIAL OF UT15C SR IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION FREEDOM EXT", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01027949", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "1045914", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "1675.00", "Date_of_Payment": "12/05/2013", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "31639986", "Name_of_Associated_Covered_Drug_or_Biological1": "ORENITRAM", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "AN OPEN-LABEL EXTENSION TRIAL OF UT15C SR IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION FREEDOM EXT", "Research_Information_Link": "http://www.clinicaltrials.gov/ct2/show/NCT01027949", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "1045914", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "1620.00", "Date_of_Payment": "08/15/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214164564", "Name_of_Associated_Covered_Drug_or_Biological1": "ORENITRAM", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "TRIAL OF THE EARLY COMBINATION OF ORAL TREPROSTINIL WITH A PDE-5 INHIBITOR OR ERA IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION FREEDOM EV", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01560624", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "1045914", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "1253.00", "Date_of_Payment": "09/05/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214164570", "Name_of_Associated_Covered_Drug_or_Biological1": "ORENITRAM", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "TRIAL OF THE EARLY COMBINATION OF ORAL TREPROSTINIL WITH A PDE-5 INHIBITOR OR ERA IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION FREEDOM EV", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01560624", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "1045914", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "1065.00", "Date_of_Payment": "08/08/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214164558", "Name_of_Associated_Covered_Drug_or_Biological1": "ORENITRAM", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "AN OPEN LABEL LONG TERM STUDY OF ORAL TREPROSTINIL IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01560637", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "1045914", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "956.00", "Date_of_Payment": "08/15/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214164562", "Name_of_Associated_Covered_Drug_or_Biological1": "ORENITRAM", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "TRIAL OF THE EARLY COMBINATION OF ORAL TREPROSTINIL WITH A PDE-5 INHIBITOR OR ERA IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION FREEDOM EV", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01560624", "Context_of_Research": "NA"}, {"Physician_Profile_ID": "1045914", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "United Therapeutics Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000010739", "Total_Amount_of_Payment_USDollars": "163.00", "Date_of_Payment": "08/15/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "214164560", "Name_of_Associated_Covered_Drug_or_Biological1": "ORENITRAM", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "TRIAL OF THE EARLY COMBINATION OF ORAL TREPROSTINIL WITH A PDE-5 INHIBITOR OR ERA IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION FREEDOM EV", "Research_Information_Link": "http://clinicaltrials.gov/ct2/show/NCT01560624", "Context_of_Research": "NA"}]